First Manhattan’s Lucid Diagnostics LUCD Stock Holding History

First Manhattan’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$372K	Hold	323,450	–	–	﹤0.01%	622
2025 Q4	$353K	Hold	323,450	–	–	﹤0.01%	619
2025 Q3	$327K	Hold	323,450	–	–	﹤0.01%	610
2025 Q2	$372K	Buy	323,450 +310,850	+2,467%	+$401K	﹤0.01%	584
2025 Q1	$18.8K	Hold	12,600	–	–	﹤0.01%	675
2024 Q4	$10.3K	Hold	12,600	–	–	﹤0.01%	679
2024 Q3	$10.3K	Hold	12,600	–	–	﹤0.01%	680
2024 Q2	$10.3K	Buy	+12,600	New	+$10.7K	﹤0.01%	667

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

First Manhattan's LUCD Position: Q1 2026 in Review

First Manhattan held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 323,450 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

First Manhattan first reported a position in LUCD in Q2 2024 and has held it in 8 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

First Manhattan held 323,450 shares of Lucid Diagnostics worth $372K as of Q1 2026.
First Manhattan left its Lucid Diagnostics share count unchanged in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #622 holding.
First Manhattan first reported a position in Lucid Diagnostics in Q2 2024 and has held it in 8 quarters since.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.